Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
CC transcript
Quarterly results
Appointed director
Viracta Therapeutics, Inc. (VIRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/04/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FORM 8-K",
"Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus -Associated Cancers",
"Corporate Presentation"
08/14/2023 8-K Quarterly results
Docs: "Viracta Therapeutics, Inc. Selected Balance Sheet Highlights June 30, December 31, 2023 2022 Cash, cash equivalents and short-term investments $ 72,867 $ 91,043 Total assets $ 76,859 $ 95,991 Total liabilities $ 36,077 $ 34,888 Stockholders' equity $ 40,782 $ 61,103 Viracta Therapeutics, Inc. Condensed Consolidated Statement of Operations and Comprehensive Loss Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Operating expenses: Research and development $ 8,197 $ 6,324 $ 15,804 $ 12,420 General and administrative 4,253 4,181 8,853 8,517 Total operating expenses 12,450 10,505 24,657 20,937 Loss from operations Total other expense Net loss Unrealized gain on short-term investments — 63 — Comprehensive loss Net loss per share, basic and diluted $ $ $ $ Weight..."
08/07/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Head of Investor Relations"
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/08/2023 8-K Quarterly results
Docs: "-- Financial tables attached – Viracta Therapeutics, Inc. Selected Balance Sheet Highlights March 31, December 31, 2023 2022 Cash, cash equivalents and short-term investments $ 80,332 $ 91,043 Total assets $ 85,781 $ 95,991 Total liabilities $ 34,668 $ 34,888 Stockholders' equity $ 51,113 $ 61,103 Viracta Therapeutics, Inc. Condensed Consolidated Statement of Operations and Comprehensive Loss Three Months Ended March 31, 2023 2022 Operating expenses: Research and development $ 7,607 $ 6,096 General and administrative 4,600 4,336 Total operating expenses 12,207 10,432 Loss from operations Total other expense Net loss Unrealized gain on short-term investments 91 — Comprehensive loss Net loss per share, basic and diluted $ $ Weighted-average common shares outstanding, basic and diluted 3..."
05/02/2023 8-K Quarterly results
03/31/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/13/2023 8-K Quarterly results
Docs: "Viracta Therapeutics, Inc. Selected Balance Sheet Highlights December 31, 2022 2021 Cash, cash equivalents and short-term investments $ 91,043 $ 103,554 Total assets $ 95,991 $ 108,552 Total liabilities $ 34,888 $ 14,181stockholders' equity $ 61,103 $ 94,371 Viracta Therapeutics, Inc. Condensed Consolidated Statement of Operations and Comprehensive Loss Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Operating expenses: Research and development $ 6,703 $ 7,303 $ 26,262 $ 23,861 Purchased and acquired in-process research and development — — — 88,478 General and administrative 4,871 4,015 24,327 15,437 Total operating expenses 11,574 11,318 50,589 127,776 Gain on Royalty Purchase Agreement — — — 13,500 Loss from operations Total other income 1,248 1,392 Net loss..."
11/10/2022 8-K Quarterly results
09/19/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Executive Employment Agreement by and between the Company and Mark Rothera",
"Separation Agreement and Release by and between the Company and Ivor Royston",
"Viracta Therapeutics Announces Chief Executive Officer Leadership Succession to Drive the Next Phase of the Company's Strategic Development and Growth"
08/26/2022 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT is entered into as of August 26, 2022, by and among SILICON VALLEY BANK, a California corporation with an office located at 3003 Tasman Drive, Santa Clara, CA 95054, as collateral agent , the Lenders listed on Schedule 1.1 thereof or otherwise a party thereto from time to time including SVB in its capacity as a Lender, and OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 , Viracta Therapeutics, Inc., a Delaware corporation, and Viracta Subsidiary, Inc., Delaware corporation, each with offices located at 2533 S Coast Hwy 101, Suite 210, Cardiff, CA 92007 . A. Collateral Agent, Borrower and Lenders have en..."
08/11/2022 8-K Quarterly results
08/09/2022 8-K Quarterly results
06/08/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
04/27/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
04/15/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/16/2022 8-K Quarterly results
Docs: "Viracta Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update Final Phase 1b/2 data showing promising and durable signal of efficacy for Nana-val in patients with relapsed/refractory Epstein-Barr virus-positive lymphoma featured in an oral presentation at ASH 2021 Pivotal NAVAL-1 trial of Nana-val for the treatment of EBV+ lymphoma is enrolling patients and an update on the initial cohort expanding into Stage 2 is anticipated in the second half of 2022 Preliminary safety and efficacy data from the Phase 1b/2 trial of Nana-val for the treatment of advanced EBV+ solid tumors is expected in the second half of 2022 Cash balance of $103.6 million as of December 31, 2021, expected to be sufficient to fund operations into mid-2024"
11/10/2021 8-K Quarterly results
Docs: "Viracta Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update Announced that final results of Phase 1b/2 trial of nanatinostat and valganciclovir in relapsed/refractory Epstein-Barr virus-positive lymphoma were selected for an oral presentation at the 2021 American Society of Hematology Annual Meeting Continued the global expansion of pivotal NAVAL-1 trial of Nana-val in R/R EBV+ lymphoma; multiple U.S. and international sites now open for enrollment Initiated Phase 1b/2 trial of Nana-val in patients with EBV+ solid tumors; preliminary data anticipated in 2022 Announced that preclinical data on vecabrutinib was selected for oral and poster presentations at ASH Secured expanded $50 million credit facility from Silicon Valley Bank and Oxford Finance Cash and..."
11/05/2021 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob...
Docs: "Viracta Therapeutics Secures $50 Million Credit Facility from Silicon Valley Bank and Oxford Finance"
10/06/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Viracta Therapeutics Initiates Phase 1b/2 Trial in Epstein-Barr Virus-Positive Solid Tumors Multinational trial expands Viracta’s clinical-stage pipeline beyond EBV+ lymphoproliferative disorders"
08/23/2021 8-K Quarterly results
08/16/2021 8-K Quarterly results
08/12/2021 8-K Quarterly results
Docs: "Viracta Therapeutics Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates",
"Corporate Presentation of Viracta Therapeutics, Inc"
07/21/2021 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : July 21, 2021 VIRACTA THERAPEUTICS, INC. Delaware 000-51531 94-3295878 File Number) Identification No.) 2533 S Coast Hwy 101, Suite 210 Cardiff, California 92007 Registrant's telephone number, including area code: 400-8470 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under th...",
"Viracta Therapeutics Announces FDA Clearance of IND Application for Phase 1b/2 Trial in Epstein-Barr Virus-Positive Solid Tumors"
07/06/2021 8-K Quarterly results
05/28/2021 8-K Quarterly results
05/12/2021 8-K Quarterly results
04/14/2021 8-K Quarterly results
04/01/2021 8-K Quarterly results
03/23/2021 8-K Quarterly results
03/04/2021 8-K Quarterly results
02/24/2021 8-K Quarterly results
02/22/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy